Page last updated: 2024-11-05

cresidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cresidine, also known as 2-methylaniline, is an organic compound with the formula CH3C6H4NH2. It is a colorless liquid that is soluble in water and organic solvents. Cresidine is an important intermediate in the synthesis of dyes, pharmaceuticals, and other chemicals. It is also used as a solvent and as a component of photographic developers. Cresidine is synthesized by the nitration of toluene followed by reduction of the nitro group. The effects of cresidine on human health are not well-studied, but it is known to be a skin and eye irritant. Cresidine is studied due to its potential use in the synthesis of various industrial and pharmaceutical compounds. It is also investigated for its biological activity and its ability to act as a building block for more complex molecules.'

cresidine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8445
CHEMBL ID398755
CHEBI ID82307
SCHEMBL ID55544
MeSH IDM0061236

Synonyms (85)

Synonym
BIDD:GT0303
cresidine
120-71-8
o-anisidine, 5-methyl-
3-amino-p-cresol methyl ether
1-amino-2-methoxy-5-methylbenzene
3-amino-4-methoxytoluene
krezidin
nsc6162
4-methyl-2-aminoanisole
nci-c02982
nsc-6162
benzenamine, 2-methoxy-5-methyl-
4-methoxy-m-toluidine
p-cresidine
5-methyl-o-anisidine
2-methoxy-5-methylaniline
2-methoxy-5-methylbenzenamine
wln: zr c1 fo1
2-amino-4-methylanisole
2-methoxy-5-methyl-aniline
nsc406904
nsc-406904
inchi=1/c8h11no/c1-6-3-4-8(10-2)7(9)5-6/h3-5h,9h2,1-2h
NCGC00090863-01
ccris 183
c.i. azoic red 83
brn 0637071
azoic red 36
m-amino-p-cresol, methyl ester
ortho-anisidine, 5-methyl-
6-methoxy-m-toluidine
para-cresidine
nsc 406904
einecs 204-419-1
p-kresidin [czech]
3-amino-para-cresol, methyl ether
krezidine
hsdb 4107
2-amino-p-cresol methyl ether
meta-amino-para-cresol, methyl ether
2-methoxy-5-methylaniline, 99%
CHEMBL398755
chebi:82307 ,
MLS002152926
smr001224526
zzt ,
M0115
AKOS000119398
NCGC00090863-03
NCGC00090863-02
C19216
NCGC00259456-01
NCGC00254113-01
cas-120-71-8
dtxsid1020350 ,
tox21_201907
tox21_300012
dtxcid30350
ec 204-419-1
4c11l78ur3 ,
3-13-00-01577 (beilstein handbook reference)
unii-4c11l78ur3
p-kresidin
FT-0612802
AM20050311
SCHEMBL55544
5-methyl-2-methoxyaniline
2-amino -4-methylanisole
1-amino-3-methyl-6-methoxybenzene
para-cresidine [iarc]
m-amino-p-cresol methyl ester
2-methoxy-5-methylbenzeneamine
p-cresidine [hsdb]
AC-23656
J-509828
F2190-0481
mfcd00007815
2-methoxy-5-methylaniline, analytical standard
2-methoxy-5-methylaniline 100 microg/ml in acetonitrile
AS-30235
Q309528
STL196541
EN300-20247
Z104477476

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" However, the incidences of multiple mammary gland tumors were significantly increased in dosed females from both lines."( Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue.
Braun, AG; Rao, GN; Russfield, A; Seilkop, S; Tennant, RW, 1993
)
0.29
" Increased tumor susceptibility associated with a reduction in p53 dosage may be dependent on neoplastic progression rather than initiation and promotional events elicited by p-cresidine."( Evaluation of cytotoxicity, cell proliferation, and genotoxicity induced by p-cresidine in hetero- and nullizygous transgenic p53 mice.
Delker, DA; Gollapudi, BB; Yano, BL, 2000
)
0.73
" Findings related to the administration of chlorpromazine in the 26-week study were limited to minimal uterine and ovarian atrophy in p53 wild-type mice dosed with 10 mg/kg chlorpromazine hydrochloride."( Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.
Evans, EW; Frank, DW; Freeman, GB; MacDonald, JS; Petruska, JM,
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency15.72090.000221.22318,912.5098AID1259247
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency15.84890.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency54.28900.001022.650876.6163AID1224838; AID1224839; AID1224893
pregnane X nuclear receptorHomo sapiens (human)Potency66.29430.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.45410.000229.305416,493.5996AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency70.79460.001019.414170.9645AID588537
aryl hydrocarbon receptorHomo sapiens (human)Potency61.44160.000723.06741,258.9301AID743085; AID743122
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID307626Solubility in water
AID307625Partition coefficient, log P of the compound
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (18.75)18.7374
1990's4 (25.00)18.2507
2000's8 (50.00)29.6817
2010's1 (6.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.08 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index38.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]